Literature DB >> 21129929

Catheter-related bloodstream infections: catheter management according to pathogen.

Leonidia Leonidou1, Charalambos A Gogos.   

Abstract

Central-line access is an essential part of modern healthcare practice; however, catheter-related bloodstream infection is a major problem that causes substantial morbidity and mortality, and excess length of stay and cost. The risk of infection depends on the type of device, the site of insertion, the underlying conditions and the appropriate prevention measures taken during catheter insertion. Management of catheter-related bloodstream infection involves deciding on catheter removal, antimicrobial catheter lock solution and the type and duration of systemic antimicrobial therapy. Systemic antimicrobial use is essential but, although generally effective in controlling sepsis, it often fails to sterilise the line, increasing the incidence of complications or recurrence. The decision regarding whether the catheter should be removed or retained is therefore crucial. One of the major factors to be considered is the type of organism involved in the catheter-related infection. This review outlines the epidemiology, pathogenesis, diagnosis, microbiology and management of catheter-related infections, mainly focusing on the management of the intravascular device according to the pathogen.
Copyright © 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21129929     DOI: 10.1016/j.ijantimicag.2010.11.004

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  8 in total

1.  Molecular investigation of bacterial communities on intravascular catheters: no longer just Staphylococcus.

Authors:  L Zhang; J Gowardman; M Morrison; L Krause; E G Playford; C M Rickard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-06       Impact factor: 3.267

2.  Peripherally inserted central catheter-related bloodstream infection caused by Kocuria marina in an elderly man.

Authors:  Nobuaki Mori; Yuichi Nishihara; Hideki Tayama; Akiko Higuchi; Yasuko Aoki
Journal:  Infection       Date:  2017-01-19       Impact factor: 3.553

3.  Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant staphylococci.

Authors:  Haroon Mohammad; Abdelrahman S Mayhoub; Mark Cushman; Mohamed N Seleem
Journal:  J Antibiot (Tokyo)       Date:  2014-10-15       Impact factor: 2.649

Review 4.  Central venous catheter (CVC) removal for patients of all ages with candidaemia.

Authors:  Susanne Janum; Arash Afshari
Journal:  Cochrane Database Syst Rev       Date:  2016-07-11

5.  Bacillus cereus catheter related bloodstream infection in a patient with acute lymphoblastic leukemia.

Authors:  N Gurler; L Oksuz; M Muftuoglu; Fd Sargin; Sk Besisik
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-01-18       Impact factor: 2.576

6.  Comparative Analysis of Bacterial Community Composition and Structure in Clinically Symptomatic and Asymptomatic Central Venous Catheters.

Authors:  Franziska A Stressmann; Elodie Couve-Deacon; Delphine Chainier; Ashwini Chauhan; Aimee Wessel; Sylvaine Durand-Fontanier; Marie-Christine Escande; Irène Kriegel; Bruno Francois; Marie-Cécile Ploy; Christophe Beloin; Jean-Marc Ghigo
Journal:  mSphere       Date:  2017-09-27       Impact factor: 4.389

7.  In Vitro Antimicrobial Evaluation, Single-Point Resistance Study, and Radiosterilization of Novel Pyrazole Incorporating Thiazol-4-one/Thiophene Derivatives as Dual DNA Gyrase and DHFR Inhibitors against MDR Pathogens.

Authors:  Hazem Ali Mohamed; Yousry A Ammar; Gameel A M Elhagali; Hassan A Eyada; Dina S Aboul-Magd; Ahmed Ragab
Journal:  ACS Omega       Date:  2022-02-03

Review 8.  Bench-to-bedside review: Challenges of diagnosis, care and prevention of central catheter-related bloodstream infections in children.

Authors:  Susanne Janum; Walter Zingg; Volker Classen; Arash Afshari
Journal:  Crit Care       Date:  2013-08-28       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.